ALTIMMUNE, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
ALTIMMUNE, INC. (ALT) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$85.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-06
- ALTIMMUNE, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$85.25M.
- ALTIMMUNE, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$88.40M.
- ALTIMMUNE, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$65.70M.
- ALTIMMUNE, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$72.75M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$85.25M 10-K · filed 2026-03-06 | |
| 2024-12-31 | -$88.40M 10-K · filed 2026-03-06 | |
| 2023-12-31 | -$65.70M 10-K · filed 2025-02-27 | |
| 2022-12-31 | -$72.75M 10-K · filed 2024-03-27 | |
| 2021-12-31 | -$78.58M 10-K · filed 2023-02-28 | -$78.58M 10-K · filed 2022-03-15 |
| 2020-12-31 | -$50.74M 10-K · filed 2022-03-15 | |
| 2019-12-31 | -$18.56M 10-K · filed 2021-02-25 | |
| 2018-12-31 | -$38.98M 10-K · filed 2020-03-27 | |
| 2017-12-31 | -$27.81M 10-K · filed 2019-04-01 | |
| 2016-12-31 | -$8.18M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |